Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-debate-20260410-075012-32bac138_task_9aae8fc5",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "scidex.core.llm.complete",
  "action": "critique",
  "content": "# Critical Evaluation of Chaperone Selectivity Hypotheses\n\n## Hypothesis 1: Co-chaperone Heterogeneity (DNAJB6/DNAJB2)\n\n**Weak Links:**\n- The \"client code\" is descriptive terminology lacking mechanistic detail—how do specific J-protein/HSP70 kinetic differences translate to conformational discrimination?\n- DNAJB6 anti-amyloid activity may reflect kinetic suppression of nucleation rather than selective recognition of pre-formed pathogenic seeds\n- Overlapping J-protein functionality and redundancy questions whether this provides high-fidelity selectivity\n\n**Counter-Evidence:**\n- Germline DNAJB6 mutations cause myofibrillar myopathy (loss-of-function), not gain of specific conformational recognition, suggesting the mechanism is general quality control rather than pathologic selectivity\n- No structural data demonstrating differential J-protein binding to distinct conformational states\n\n**Falsifying Experiment:**\n- Compare DNAJB6 binding affinity for pre-formed fibrils vs. early-stage oligomers vs. monomers using surface plasmon resonance. If DNAJB6 binds monomers with equal or greater affinity, selectivity is kinetic, not conformational.\n\n**Revised Confidence:** 0.45 (from 0.65)\n\n---\n\n## Hypothesis 2: CK2-Phosphorylation of HSP90α\n\n**Weak Links:**\n- CK2 is one of the most pleiotropic kinases in the proteome (thousands of substrates); functional specificity for pathologic conformer recognition is mechanistically implausible\n- T115 and S226 are not well-validated as physiologically relevant regulatory sites; literature is correlative rather than mechanistic\n- The \"allosteric remodeling\" claim lacks structural data (HSP90 phosphorylation has been studied primarily on S231 in the middle domain)\n\n**Counter-Evidence:**\n- CK2 inhibitors (CX-4945) are in clinical trials for cancer—chronic CK2 inhibition would have pleiotropic effects that confound interpretation\n- No evidence that HSP90 phosphorylation state correlates with pathogenic conformer burden in patient samples\n\n**Falsifying Experiment:**\n- Test whether CK2 knockdown or CX-4945 treatment alters HSP90 binding to recombinant pathologic tau conformers in vitro. If CK2 inhibition does not change client discrimination, the hypothesis fails.\n\n**Revised Confidence:** 0.30 (from 0.55)\n\n---\n\n## Hypothesis 3: Exposed Amyloidogenic Segments\n\n**Weak Links:**\n- HSP70's broad substrate specificity predicts high-affinity binding to any exposed hydrophobic segment—this conflates \"prefers misfolded\" with \"distinguishes pathologic from physiologic misfolded states\"\n- Does not explain selectivity for disease-causing conformers vs. benign folding intermediates that also expose hydrophobic segments\n- Aggregation-prone sequences are shared across many aggregation-prone proteins but are not inherently pathologic\n\n**Counter-Evidence:**\n- Transient native-state fluctuations expose hydrophobic segments during normal folding—this predicts HSP70 would \"waste\" cycles on normal substrates\n- No evidence that HSP70 preferentially dissociates from early oligomers (on-pathway to fibrils) vs. late-stage seeds\n\n**Falsifying Experiment:**\n- Hydrogen-deuterium exchange mass spec comparing HSP70 binding to A53T vs. wild-type α-synuclein PFFs. If A53T (pathogenic) and WT show equivalent binding, selectivity is low. Test whether HSP70 discriminates between oligomers on the fibril pathway vs. off-pathway aggregates.\n\n**Revised Confidence:** 0.55 (from 0.70)\n\n---\n\n## Hypothesis 4: CHIP-Mediated Ubiquitination\n\n**Weak Links:**\n- CHIP recognizes linear degradation motifs (KFERL-like sequences) and HSP70-bound states, not specific conformations—the \"conformational discriminator\" framing is unsupported\n- The \"refolding zone\" concept lacks kinetic parameters and experimental validation\n- If CHIP selectively degrades pathologic conformers, loss-of-function should cause widespread neurodegeneration (not observed in CHIP knockout mice—primary phenotype is cardiac/muscle)\n\n**Counter-Evidence:**\n- CHIP knockout mice show selective vulnerability in heart and muscle, not brain (PMID: 15837799)\n- CHIP substrates include many non-pathologic clients—this questions specific conformational discrimination\n\n**Falsifying Experiment:**\n- Test whether GFP-tagged monomeric α-synuclein (non-pathologic) vs. PFFs produce equivalent HSP70-CHIP complex stability by co-IP. If monomers form equally stable complexes, selectivity is low. Quantify K48-ubiquitin chains on monomeric vs. aggregated species.",
  "tokens_used": "1114",
  "persona_id": "persona-skeptic"
}